More data needed for Glaxo's Advair-US FDA panel

WASHINGTON, May 1 (Reuters) - An increased risk of respiratory infections and pneumonia seen with GlaxoSmithKline Plc's (GSK.L)(GSK.N) high-dose Advair warrant further evaluation, a U.S. panel of experts unanimously said on Tuesday.

The U.S. Food and Drug Administration advisory panel earlier said company studies of the drug to treat chronic obstructive pulmonary disease, or COPD, showed it reduced flare-ups but does not help patients live longer.

((Reporting by Susan Heavey, editing by Martin Golan; Reuters Messaging: susan.heavey.reuters.com@reuters.net, Phone: 202-354-5848)) Keywords: GLAXOSMITHKLINE ADVAIR/STUDIES

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWBT006913